MICHAEL RAAB
CIK 1321402 · President & CEO · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$8.75M
Companies
4
Total Filings
148
Lifetime Open-Market Net
-$9.19M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | President & CEO | 1,721,034 | $5.08 | $8.75M | -$8.57M | 85 | 2026-07-17 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 0 | $14.49 | $0 | -$629.0K | 28 | 2026-04-27 |
| TPST | Director | — | $0.87 | — | $0 | 6 | 2026-01-28 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | — | — | — | $0 | 3 | 2008-03-31 |
Recent Filings · Page 2 of 15
148 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-25 | ARDX | Mixed | −20,833 | -$240.0K | EDGAR |
| 2026-02-24 | ARDX | Notice (144) | −166,666 | -$958.3K | EDGAR |
| 2026-02-23 | ARDX | Sell (S) | −45,982 | -$268.8K | EDGAR |
| 2026-02-20 | ARDX | Notice (144) | −51,100 | -$292.8K | EDGAR |
| 2026-01-28 | TPST | Grant (A) | — | $0 | EDGAR |
| 2026-01-26 | ARDX | Grant (A) | +446,220 | $0 | EDGAR |
| 2025-11-25 | ARDX | Sell (S) | −46,887 | -$259.6K | EDGAR |
| 2025-11-20 | ARDX | Notice (144) | −45,868 | -$271.1K | EDGAR |
| 2025-08-25 | ARDX | Sell (S) | −45,687 | -$271.0K | EDGAR |
| 2025-06-06 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Grant (A) | +20,414 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.